MetaCap

NewcelX (NCEL) vs Quoin Pharmaceuticals (QNRX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

NewcelX (NCEL) has outperformed Quoin Pharmaceuticals (QNRX) over the past year, losing 22.3% versus a loss of 82.1%. Over five years, NCEL leads with a -99.7% price change compared with -100.0% for QNRX. Quoin Pharmaceuticals is the larger company by market cap ($15.8 million vs $14.7 million), about 1.1 times the size.

On valuation, NewcelX trades at a lower trailing P/E (4.9x vs 7.5x for Quoin Pharmaceuticals).

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

NCEL-22.32%QNRX-82.07%
+57%-16%-89%
Nov 21, 20251 yearNov 20, 2026
NCEL-99.68%QNRX-99.99%
+5%-50%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

NCEL versus QNRX key metrics
MetricNCELQNRX
Share price$2.54$3.28
Market cap$14.67M$15.76M
1-day change-5.58%-2.35%
YTD return+33.68%-77.27%
1-year return-22.32%-82.07%
5-year return-99.65%-99.99%
P/E ratio (TTM)4.887.45
EPS (TTM)$0.52$0.44
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-8.30M$-15.80M
52-week high$5.12$23.50
52-week low$1.83$3.18
Distance from 52-week high-50.39%-86.04%
Analyst consensusnonenone
Avg. price target upside+805.51%+565.55%
Average volume13.34K541.26K
Shares outstanding5.78M4.80M
Employees94
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • NCEL has outperformed QNRX by 59.7 percentage points over the past year.
  • Quoin Pharmaceuticals trades at a higher earnings multiple (7.5x vs 4.9x trailing P/E).

About NewcelX

NCEL stock →

NewcelX Ltd., a biopharmaceutical company, engages in developing transformative stem-cell-derived therapies for Diabetes. The company develops NCEL-101, a cellular therapy product based on enriched pancreatic islet-like clusters for the treatment of Type 1 diabetes and Type 2 insulin dependent diabetes; AstroRx, an off-the-shelf cryopreserved cell therapy product for the treatment of Amyotrophic Lateral Sclerosis and neurodegenerative indications; and Dual Orexin-Receptor Agonist (DOXA), a small molecules platform for the treatment of sleep disorders, Neurodegenerative/ neuroinflammation diseases, and Diabetes Associated Neurological Disorders.

Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees

About Quoin Pharmaceuticals

QNRX stock →

Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis.

Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees

NCEL vs QNRX FAQ

Which is bigger, NewcelX or Quoin Pharmaceuticals?

Quoin Pharmaceuticals (QNRX) is larger, with a market capitalization of $15.76M compared with $14.67M for NewcelX (NCEL).

Which stock has performed better over the past year, NCEL or QNRX?

NCEL returned -22.32% over the past 12 months, compared with -82.07% for QNRX (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, NCEL or QNRX?

NCEL has the lower trailing P/E at 4.9, versus 7.5 for QNRX. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Are NewcelX and Quoin Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons